10-Q: Agilent Q3 Revenue Jumps 10%, Net Income Up 19% Amid Restructuring

Agilent Technologies reports strong third-quarter revenue growth of 10% and a 19% increase in net income, driven by its Life Sciences and Diagnostics Markets segment, despite ongoing restructuring costs and tariff impacts.

Summary

• Net revenue for the three months ended July 31, 2025, increased 10% to $1,738 million, compared to $1,578 million in the prior year period.
• Net revenue for the nine months ended July 31, 2025, increased 6% to $5,087 million, compared to $4,809 million in the prior year period.
• Net income for the three months ended July 31, 2025, was $336 million, up from $282 million in the prior year period.
• Net income for the nine months ended July 31, 2025, was $869 million, down from $938 million in the prior year period.
• Diluted earnings per share (EPS) for the three months ended July 31, 2025, was $1.18, up from $0.97 in the prior year period.
• Diluted EPS for the nine months ended July 31, 2025, was $3.05, down from $3.20 in the prior year period.
• Gross margin decreased by 3 percentage points to 51.1% for the three months and by 2 percentage points to 52.2% for the nine months ended July 31, 2025, primarily due to higher tariffs, shipping costs, and unfavorable product mix.
• Operating margin for the three months ended July 31, 2025, was 20.7% (flat year-over-year), and for the nine months, it decreased by 2 percentage points to 20.4%.
• Cash provided by operating activities for the nine months ended July 31, 2025, was $1,014 million, a decrease from $1,270 million in the same period last year.
• The Life Sciences and Diagnostics Markets segment saw revenue growth of 14% in the three months and 9% in the nine months, with the BIOVECTRA acquisition contributing approximately 2 percentage points to overall revenue growth.
• Restructuring expenses totaled $17 million for the three months and $74 million for the nine months ended July 31, 2025, as part of plans to optimize management structure and reduce costs.
• The effective tax rate for the three months ended July 31, 2025, was 8.2%, benefiting from a $28 million release of tax reserves.
• The board of directors approved a new $2.0 billion share repurchase program (2024 program) effective August 1, 2024, following the near completion of the 2023 program with $34 million remaining authorization.
• Cash dividends paid increased to $0.248 per common share for the three months and $0.744 per common share for the nine months ended July 31, 2025.

Sentiment

Score: 6

Explanation: The company reported strong Q3 revenue and net income growth, driven by key segments and acquisitions. However, year-to-date net income and cash from operations declined, and gross and operating margins faced pressure from tariffs, shipping costs, and unfavorable mix. Management expresses optimism for long-term market health and plans to mitigate cost pressures, but acknowledges ongoing customer budget constraints. The new share repurchase program is a positive signal, balancing the mixed financial performance.

Positives

• Net revenue for the three months ended July 31, 2025, increased by a strong 10% to $1,738 million.
• Net income for the three months ended July 31, 2025, increased by 19% to $336 million.
• Diluted EPS for the three months ended July 31, 2025, rose to $1.18 from $0.97.
• Revenue growth was observed across all segments and geographic regions in the three months ended July 31, 2025.
• The BIOVECTRA acquisition contributed approximately 2 percentage points to overall revenue growth for both the three and nine months ended July 31, 2025.
• The Life Sciences and Diagnostics Markets segment demonstrated robust revenue growth of 14% in the three months and 9% in the nine months.
• A significant tax benefit of $28 million from the release of tax reserves lowered the effective tax rate to 8.2% for the three months ended July 31, 2025.
• A new $2.0 billion share repurchase program (2024 program) was approved, signaling continued commitment to shareholder returns.
• Cash dividends per common share increased to $0.248 for the three months and $0.744 for the nine months ended July 31, 2025.
• Headcount increased to approximately 18,000 at July 31, 2025, from 17,400 at July 31, 2024, indicating business expansion.
• Management expressed optimism about the long-term health of key end markets and expects to substantially mitigate tariff impacts during fiscal year 2026.
• Inventory days on-hand improved to 107 days as of July 31, 2025, from 122 days as of July 31, 2024.

Negatives

• Net income for the nine months ended July 31, 2025, decreased by 7.4% to $869 million.
• Diluted EPS for the nine months ended July 31, 2025, decreased by 4.7% to $3.05.
• Cash provided by operating activities for the nine months ended July 31, 2025, decreased by $256 million to $1,014 million.
• Gross margin declined by 3 percentage points in the three months and 2 percentage points in the nine months, impacted by higher tariffs, shipping costs, unfavorable product mix, higher wages, and variable pay.
• Operating margin decreased by 2 percentage points for the nine months ended July 31, 2025.
• Interest expense increased to $85 million for the nine months ended July 31, 2025, from $64 million in the prior year period.
• Interest income decreased to $45 million for the nine months ended July 31, 2025, from $56 million, primarily due to lower cash balances.
• A net loss of $28 million on equity securities and $15 million loss on impairment of investments were recorded for the nine months ended July 31, 2025.
• A $14 million settlement loss related to the Netherlands defined benefit pension plan was recognized for the nine months ended July 31, 2025.
• Restructuring expenses of $74 million for the nine months ended July 31, 2025, continue to impact profitability.
• Customer capital budgets, including those from the U.S. federal government, remain constrained.
• Recent tariff changes adversely impacted costs of revenue in the third quarter.
• The Agilent CrossLab segment experienced a 1 percentage point unfavorable foreign currency impact on revenue growth for the nine months ended July 31, 2025.
• The Applied Markets segment revenue was flat for the nine months ended July 31, 2025.
• Days sales outstanding (DSO) increased to 72 days as of July 31, 2025, from 70 days as of July 31, 2024.
• Cash used by inventory was $72 million for the nine months ended July 31, 2025, compared to cash provided of $15 million for the same period in 2024.

Risks

• General economic conditions, including slower global growth, increasing interest rates, and inflationary pressures, may adversely affect operating results and financial condition.
• Declines in customer markets or failure to grow as anticipated could reduce demand, increase excess inventory, intensify price pressure, and impair investment portfolio value.
• International sales and operations are subject to economic, political, and foreign currency risks, including exchange rate fluctuations, geopolitical instability, and changes in trade policies and tariffs.
• Dependence on centralized accounting and tax processes in India and Malaysia exposes operations to risks from changes in conditions in those countries.
• Failure to introduce successful new products and services in a timely manner could lead to product obsolescence and harm operating results.
• Demand for products and services is sensitive to customer capital spending policies, R&D budgets, and government funding policies, which are difficult to forecast.
• Recent and dynamic government rule-making and policy changes, including tariffs, could increase costs and affect markets and customers.
• Inadequate funding for U.S. federal government agencies could impact product sales to customers receiving federal funding.
• Failure to adjust purchases to changing market conditions or accurately estimate customer demand could lead to excess/obsolete inventories or inability to meet demand.
• Inability to retain and hire key personnel, especially in highly technical specialties, could hinder business expansion.
• Strategic initiatives to adjust cost structure (e.g., restructuring) may distract management, slow product improvements, or fail to realize anticipated benefits.
• Acquisitions, strategic investments, alliances, joint ventures, and divestitures may result in unexpected financial results, integration difficulties, and significant costs.
• Consolidation and acquisitions of competitors could increase market share for rivals, adversely affecting Agilent's business.
• Public health crises, such as pandemics, may adversely impact operations, supply chain, sales, and delivery of products and services.
• Failure to maintain an effective system of internal controls could lead to inaccurate financial reporting and loss of investor confidence.
• Non-compliance with various governmental regulations (health, safety, data privacy, anti-bribery, import/export) could result in significant expenses, product recalls, or penalties.
• Extensive regulation by the FDA and similar foreign agencies, with failure to comply leading to warning letters, fines, injunctions, or inability to sell products.
• Compliance with complex regulations for toxic substances (e.g., TSCA) and potential civil penalties or criminal prosecution for non-compliance.
• Failure to comply with government contracting laws and regulations could result in penalties, contract termination, or debarment from future contracts.
• Improper conduct by employees, agents, or business partners could harm reputation, lead to investigations, lawsuits, and significant penalties.
• Evolving and diverging expectations from regulators and stakeholders on corporate governance and sustainability-related matters could impact risk exposure and financial conditions.
• Environmental contamination from past and ongoing operations could subject the company to substantial liabilities.
• Environmental laws and regulations expose the company to risks and could result in significant liabilities and costs, including potential changes due to climate change legislation.
• Issues in the development, deployment, and use of artificial intelligence (AI) technologies may result in reputational harm, regulatory action, or legal liability, including risks from inaccurate/biased algorithms, intellectual property concerns, and evolving regulatory environment.
• Third parties may claim intellectual property infringement, leading to costly litigation, licensing expenses, or injunctions.
• Failure to enforce intellectual property rights could lead to competitive injury.
• Operating results may suffer if manufacturing capacity does not match product demand, leading to excess capacity costs or inability to fulfill orders.
• Dependence on contract manufacturing and outsourcing (logistics, IT, administrative functions) may adversely affect the ability to bring products to market, damage reputation, or impair effective operation.
• Loss to factories, facilities, or distribution system due to catastrophe (fire, flood, terrorism, extreme weather, earthquakes) could seriously harm operations.
• Significant disruption in, or breach of security of, information technology systems, or failure to implement new systems successfully, could adversely affect business.
• Retirement and post-retirement pension plans are subject to financial market risks that could adversely affect future results and cash flows.
• Changes in tax laws, unfavorable resolution of tax examinations, or exposure to additional tax liabilities could materially affect results.
• If tax incentives change or cease to be in effect, income taxes could increase significantly.
• Outstanding debt and future debt incurrence could adversely affect financial condition, liquidity, and results of operations.
• Inability to assure continued payment of dividends on common stock.
• Adverse conditions in the global banking industry and credit markets may adversely impact the value of cash investments or impair liquidity.

Future Outlook

Management's primary focus remains on enhancing customer experience, delivering differentiated product solutions, and driving productivity improvements. While customer capital budgets, including those from the U.S. federal government, continue to be constrained, signs of a steady recovery are observed. The company remains optimistic about the long-term health of its key end markets and expects to substantially mitigate the adverse impact of recent tariff changes on costs of revenue during fiscal year 2026. Mitigation strategies for inflationary and tariff-related pressures are actively being pursued through supply chain optimization, targeted pricing actions, and other cost-efficiency initiatives to protect margins and sustain long-term growth. Agilent will continue to invest in expanding and improving its applications and solutions portfolio, leverage its liquid chromatography and liquid chromatography mass spectrometry platforms for growth in life sciences, and remains positive about growth in diagnostic and clinical markets. The CDMO business is well positioned for growing demand for therapeutic oligos. The company expects to contribute approximately $4 million to its defined benefit plans during the remainder of 2025 and anticipates total capital expenditures of approximately $400 million for the current year, primarily for manufacturing capacity expansion in Frederick, Colorado. The potential impacts of the One Big Beautiful Bill Act (OBBBA) on fiscal year 2026 and beyond, and Pillar Two rules on future periods, are being assessed, with no material impact expected in the current fiscal year for either.

Management Comments

• "Our primary focus remains on enhancing our customers experience, delivering differentiated product solutions and driving productivity improvements."
• "While customer capital budgets, including those of customers receiving funding from the U.S. federal government, continue to be constrained, we are seeing signs of a steady recovery."
• "We also remain optimistic about the long-term health of our key end markets."
• "While the recent tariff changes adversely impacted our costs of revenue in the third quarter, we expect to substantially mitigate the impact during our fiscal year 2026."
• "With inflationary and tariff-related pressures remaining fluid, we are actively pursuing mitigation strategies through supply chain optimization, targeted pricing actions, and other cost-efficiency initiatives to protect margins and sustain long-term growth."
• "We continue to leverage our liquid chromatography and liquid chromatography mass spectrometry platforms to maximize our growth via key vectors across our markets, making us optimistic about our long-term growth opportunities in the life sciences markets."
• "We remain positive about the growth in our diagnostic and clinical markets around our OMNIS platforms."
• "Market demand for therapeutic oligo continues to grow, and our CDMO business is well positioned to serve expanding customer requirements."
• "We will also continue to invest in research and development, invest in expanding and improving our applications and solutions portfolio and seek to expand our position in developing countries and emerging markets."
• "We also anticipate continued steady market recovery and are optimistic about our long-term growth opportunities in the applied markets as our broad portfolio of products and solutions are well suited to address customer needs."
• "We will continue to invest in expanding and improving our application-focused solutions that include instruments and software."

Industry Context

Agilent operates in highly competitive life sciences, diagnostics, and applied markets, characterized by rapid technological advancements and frequent new product introductions. The company's strategy of providing integrated application-focused solutions, including instruments, software, services, and consumables, aligns with broader industry trends towards comprehensive laboratory workflow support. Growth in the pharmaceutical and biopharmaceutical sector, particularly in contract development and manufacturing (CDMO) and nucleic acid solutions, reflects increasing demand for advanced therapeutics. The diagnostics and clinical market also remains a key growth area, driven by cancer diagnostics and companion diagnostics. The industry faces challenges from global economic conditions, foreign currency fluctuations, and evolving trade policies, with tariffs specifically impacting costs of revenue. Customer capital budgets, especially from government-funded entities, remain a constraint across the industry. The increasing complexity of global data privacy regulations and the nascent, rapidly evolving legal and ethical landscape surrounding AI technologies present significant industry-wide compliance and operational challenges. Industry consolidation is noted as a risk, potentially intensifying competition.

Corporate Governance

Legal Proceedings

• Involved in lawsuits, claims, investigations, and proceedings, including intellectual property, commercial, real estate, environmental, and employment matters, arising in the ordinary course of business.
• No matters pending are currently believed to be reasonably possible of having a material impact to the business, consolidated financial condition, results of operations, or cash flows.

Related Party Transactions

• Income of $3 million for the three months and $9 million for the nine months ended July 31, 2025, from the provision of site service costs to, and lease income from, Keysight Technologies, Inc.

Stakeholder Impact

• Shareholders: Impacted by increased dividends, a new $2.0 billion share repurchase program, and mixed financial performance (strong Q3 revenue/net income, but YTD declines in net income/EPS and margin pressures).
• Employees: Affected by ongoing restructuring plans involving workforce reductions (FY25, FY24, FY23 plans), but also by an overall increase in headcount.
• Customers: Face constrained capital budgets, particularly those receiving U.S. federal government funding, but benefit from Agilent's focus on enhancing customer experience, differentiated product solutions, and expanding its application and solutions portfolio.
• Suppliers: Subject to supply chain optimization efforts and potential changes due to tariffs.
• Creditors: Affected by the company's debt levels and compliance with credit facility covenants.

Next Steps

• Substantially complete FY25 restructuring activities by the second quarter of fiscal year 2026.
• Actively pursue mitigation strategies for inflationary and tariff-related pressures through supply chain optimization, targeted pricing actions, and other cost-efficiency initiatives.
• Continue to invest in expanding and improving applications and solutions portfolio.
• Leverage liquid chromatography and liquid chromatography mass spectrometry platforms to maximize growth in life sciences markets.
• Continue to invest in research and development.
• Seek to expand position in developing countries and emerging markets.
• Contribute approximately $4 million to defined benefit plans during the remainder of 2025.
• Assess potential impacts of the One Big Beautiful Bill Act (OBBBA) on fiscal year 2026 and beyond.
• Evaluate potential impacts of Pillar Two rules on future periods.
• The board of directors will determine and approve the timing and amounts of any future dividends.
• The 2024 share repurchase program will commence upon the termination of the 2023 repurchase program.

Key Dates

Recommendation

Agilent demonstrated strong Q3 revenue and net income growth, indicating resilience and market demand in certain segments, particularly Life Sciences and Diagnostics. The new $2.0 billion share repurchase program and increased dividends signal management's confidence and commitment to shareholder returns. However, the year-to-date decline in net income and EPS, coupled with persistent gross and operating margin pressures from tariffs, shipping costs, and unfavorable product mix, present headwinds. While management is actively pursuing mitigation strategies and is optimistic about long-term market health, the constrained customer capital budgets and ongoing restructuring costs suggest a mixed outlook. A 'hold' recommendation is appropriate as the company navigates these challenges while continuing to grow in strategic areas. Investors should monitor the effectiveness of mitigation strategies and the recovery of customer spending.

Keywords

Life sciences, Diagnostics, Applied markets, Laboratory workflow, Instruments, Software, Services, Consumables, Pharmaceutical, Biopharmaceutical, Clinical, Academic, Government, Chemicals, Advanced materials, Food safety, Environmental, Forensics, Liquid chromatography, Mass spectrometry, Cell analysis, CDMO, BIOVECTRA, Pathology, Companion diagnostics, Genomics, Next-generation sequencing, Biomolecular analysis, Agilent CrossLab, Laboratory automation, Gas chromatography, Spectroscopy, Vacuum, Remarketed instruments, SEC filing, 10-Q, Financial results, Revenue, Net income, EPS, Gross margin, Operating margin, Cash flow, Share repurchase, Dividends, Restructuring, Tariffs, Trade policies, Risk management, Corporate governance, Artificial intelligence